Compare TransMedics Group Inc (TMDX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XHB | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $150.42 | $121.36 |
52-Week Low | $61.99 | $94.86 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
XHB trades at $106.07, down 2.01% over the past day amid a bearish technical signal. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilding. Technical indicators show resistance near $108 and support at $105, while oscillators remain neutral. Recent news highlights affordability challenges from high mortgage rates and record prices, yet some sentiment improvement exists.
Outlook hinges on housing market dynamics and interest rate trends. Opportunities include potential gains from the new housing law, but risks involve persistent sales weakness and economic sensitivity. Investors should weigh legislative tailwinds against macroeconomic headwinds for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
